Doximity, Inc. · NYSE:DOCS
Doximity — Q2 2027 Earnings Presentation
24 slides from Doximity's earnings presentation, Nov 5, 2026
Slide 1: Investor Presentation
Investor Presentation NOVEMBER 2026
Slide 2: Safe Harbor and Other Information
Safe Harbor and Other Information This presentation contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact are forward-looking and involve substantial risks and uncertainties. Forward-looking statements include s
Slide 3: The #1 Healthcare Professional Network
LEADING NETWORK BLUE CHIP CLIENTS >85% 20/20 of all U.S. Top Hospitals and Health Systems The #1 Healthcare physicians1 Top Pharmaceutical Manufacturers3 Professional Network ~50% 103% of U.S. prescribers use Net Revenue our workflow tools2 Retention Rate4 1. As of 3/31/26. 2. For fiscal quarter end
Slide 4: Glaring Day-To-Day Inefficiencies
Glaring Day-To-Day Inefficiencies 70% of US HC communication still sent via fax1 75% of physicians attribute burnout to electronic health record EHR) inefficiencies2 1. Konica Minolta, “New Facts About Fax in Healthcare,ˮ 2023. 2. Tajirian et al., “The Influence of Electronic Health Record Use on Phy
Slide 5: Bringing Tech to Medicine
Bringing Tech to Medicine INSPIRED BY ENTERPRISE TECH PURPOSEBUILT FOR HEALTHCARE Networking Productivity Telehealth Dialer Voice & Dialer Video), Digital Fax, Digital eSignature, Secure Messaging, News & Scheduling On-Call Scheduling, AI Workflow Tools eSignatures Newsfeed Medical Articles & News
Slide 6: Purpose Built for Healthcare
Purpose Built for Healthcare Professional Network Newsfeed Workflow | INVESTOR PRESENTATION NOVEMBER 2026 6
Slide 7: Pathway AI Acquisition
Pathway AI Acquisition ● Half doctors, 7 years of AI experience ● Medical semantic model for max accuracy MEDICAL GRAPH Study → Drug → Outcome → Disease "ACURASYS studied the effect of cisatracurium on mortality in ARDS." | INVESTOR PRESENTATION NOVEMBER 2026 7
Slide 8: Clinical AI Suite for Physicians
Clinical AI Suite for Physicians A free, HIPAA-compliant suite of AI tools that is private to each clinician SCRIBE ASK DIALER | INVESTOR PRESENTATION NOVEMBER 2026 8
Slide 9: Doximity Ask Doc Love
Doximity Ask Doc Love “I use Ask. Personally itʼs more useful than other tools because of its cleaner interface, quicker answers, and better clinical relevance.ˮ — Dengyu Wang, MD Neurology) “Ask has been a game changer, I use it pretty much “I asked Doximity a question, then walked in to talk dail
Slide 10: Strong Engagement
Strong Engagement News Workflow AI >1M QAU >800K QAU ~½ of Workflow QAU 1, 2 1, 3 1, 3 1. QAU are unique quarterly active prescribers MD/DO/NP/PA/Pharmacist/Med Student/CRNA | | INVESTOR PRESENTATION NOVEMBER 2026 10 2. As of 12/31/25 3. For fiscal quarter ending 3/31/26
Slide 11: Engagement Throughout the Day
Engagement Throughout the Day NEWSFEED WORKFLOW/AI BOTH1 1. Doximity usage by prescribers MD/DO/NP/PA/CRNA/Pharmacist/Med Student) in fiscal quarter ending 9/30/25. For News, darker shades represent higher activity on Doximity's Newsfeed. For Workflow/AI, darker shades represent higher activity wit
Slide 12: Our Commercial Solutions
Our Commercial Solutions MARKETING HIRING ENTERPRISE WORKFLOW Educate on Latest News & Treatments Uncover Passive Candidates Reduce No-Shows & Leakage Relevance and personalization Find specialized talent Ranked #1 “Best in KLASˮ for Telehealth drive Rxʼs & Referrals 5 years running, hundreds of tho
Slide 13: Marketing Solutions
Marketing Solutions LARGEST REVENUE DRIVER MARKETING SOLUTIONS Health Systems 171 ROI2 LexisNexis Leading Network Subscription Pricing Model Pharma 73% of healthcare spend 1. Audience (e.g. specialty) is decided by Doctors1 2. Number of audience members 101 ROI3 3. Type and number of modules IQ
Slide 14: AI Search Offering
AI Search Offering Acceleration of ecosystem message Ask AI placement | INVESTOR PRESENTATION NOVEMBER 2026 14
Slide 15: Core Modules
Core Modules Newsfeed Point of Care LONG FORM VIDEO SHORT FORM POINT OF CARE FORMULARY We create customized packages for customers | INVESTOR PRESENTATION NOVEMBER 2026 15
Slide 16: Dynamic Integrated Offering
Dynamic Integrated Offering Increased unique reach Higher quality engagements HCP behavior change, increased NRx lift and impact 300 Data & Insights Inputs Proprietary Doximity, IQVIA, Brand & Content Signals AI Orchestration Engine | INVESTOR PRESENTATION NOVEMBER 2026 16
Slide 17: Large & Growing Total Accessible Market
Large & Growing Total Accessible Market $18.5B +$ Billions Total AI Search4 $7.3B $6.9B $4.3B Added Pharmaceutical Marketing 1 Health System Marketing and Staffing 2 Telehealth3 in 2026 1. Pharmaceutical Marketing TAM represents total annual marketing spend by Pharmaceutical Manufacturers to Doctors
Slide 18: Pharma Brand Opportunity
Pharma Brand Opportunity Our Penetration into $100M Our Penetration into $100M U.S. U.S. Mega Brands1 Mid-Tier Brands2 11% Signed 47% Not Signed 53% Signed 89% Not Signed 1. As of March 31, 2026. # of brands with $100m+ in US sales (based on data from Evaluate Pharma) where Doximity has revenue. 2
Slide 19: Q2 Key Revenue Metrics
Q2 Key Revenue Metrics LAND & EXPAND Number of Customers w/ $500K+ of Revenue1 Net Revenue Retention2 103% 124 $500K + Total Company + 3% y/y Top-20 Customers 106% 1. Refer to appendix for the definition of customers with trailing 12-month subscription revenue greater than $500,000. 2. Refer to appe
Slide 20: Attractive Revenue Growth & Margin Profile
Attractive Revenue Growth & Margin Profile Revenue1 Adj. EBITDA & Margin1,2 13% CAGR 15% CAGR 3 3 1. Fiscal Year ended March 31. 2. Refer to appendix for the definition and non-GAAP reconciliation of Adjusted EBITDA and Adjusted EBITDA margin. 3. FY2027 forecasts are based on the midpoint of our FY20
Slide 21: Founder-Led, Mission Driven
Founder-Led, Mission Driven Jeff Tangney Matt Sonefeldt Steve Zatz 872 CEO & Co-Founder CFO President Employees1 Lisa Greenbaum CCO Jey Balachandran CTO Amit Phull, MD Chief Medical Officer >40% in R&D1 Ben Greenberg Joel Davis John Vaughan SVP, Commercial Products SVP, Product General Counsel 1 As o
Slide 22: Company Highlights
Company Highlights Powerful network Leading digital platform effects with strong Best-in-class for doctors engagement growth profitability Massive market Veteran vertical team opportunity fueled by shift to digital & AI | INVESTOR PRESENTATION NOVEMBER 2026 22
Slide 23: Appendix: Non-GAAP Financial Measures
Appendix: Non-GAAP Financial Measures To supplement our consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP measures of financial performance: Non-GAAP g
Slide 24: Appendix: Adjusted EBITDA & Margin Non-GAAP Reconciliation
Appendix: Adjusted EBITDA & Margin Non-GAAP Reconciliation Year Ended March 31, TTM 2023 2024 2025 2026 Q2 FY27 (in thousands) Net Income $112,818 $147,582 $223,185 $196,051 $139,717 Adjustments: Acquisition and other related expenses 30 ‒ ‒ 1,616 - Stock-based compensation 47,834 47,430 72,386 121,